BFS
ARQT icon

Bare Financial Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Bare Financial Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$629 Buy
24
+7
+41% +$163 ﹤0.01% 1571
2026
Q1 		$401 Buy
+17
New +$434 ﹤0.01% 1656

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bare Financial Services's ARQT Position: Q2 2026 in Review

Bare Financial Services increased its Arcutis Biotherapeutics (ARQT) stake by 41% in Q2 2026, buying an estimated $163 and bringing the position to 24 shares worth $629. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

Bare Financial Services first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Bare Financial Services held 24 shares of Arcutis Biotherapeutics worth $629 as of Q2 2026.
  • Bare Financial Services bought 7 Arcutis Biotherapeutics shares in Q2 2026, an estimated $163.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1571 holding.
  • Bare Financial Services first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.